I-MAB American Depositary Shares

IMAB XNAS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

530M

Short interest (Oct 15)

3.2%

Net Short (Oct 29 ): 0.0%

Borrow Fee

5.37%

↓ 0.0%

Available Shares

↑ 55.9%

Price Chart

Company Overview

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Company Info

Exchange: NASDAQ

CIK: 0001778016

Asset Type: ADRC

Market Data

Market Cap: $533,681,825

Employees: 32

Status: Active

Short Interest

Current Borrow Fee 5.37%

Range: 5.18% - 5.37%

Available Shares 2M

Range: 2.2M - 4.7M

Recent Changes

Fee Change: ↑ 1.2%

Available Change: ↑ 45.8%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime